Trump's pharmaceutical tariffs could affect some drugmakers more than others ○
found
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
AbbVie, Bristol Myers Squibb and Eli Lilly appear "relatively well-positioned," while Novartis and Roche look more at risk, TD Cowen analyst Steve Scala said.